Baricitinib
Brand names: Olumiant · Active ingredient: Baricitinib
In short: OLUMIANT® is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-mod
What is Baricitinib used for?
OLUMIANT® is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
OLUMIANT is indicated for the treatment of severe alopecia areata in adults and pediatric patients 12 years of age and older.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
⚠ Boxed warning (FDA's strongest warning)
SERIOUS INFECTIONS
Patients treated with OLUMIANT are at risk for developing serious infections that may lead to hospitalization or death
. Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
If a serious infection develops, interrupt OLUMIANT until the infection is controlled.
Reported infections include:
Active tuberculosis, which may present with pulmonary or extrapulmonary disease. OLUMIANT should not be given to patients with active tuberculosis. Patients, except those with COVID-19, should be tested for latent tuberculosis before initiating OLUMIANT and during therapy. If positive, start treatment for latent infection prior to OLUMIANT use.
Invasive fungal infections, including candidiasis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
Bacterial, viral, and other infections due to opportunistic pathogens.
The risks and benefits of treatment with OLUMIANT should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with OLUMIANT including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy
. …
Baricitinib dosage
Prior to OLUMIANT treatment initiation, consider performing the following evaluations:
Active and latent tuberculosis (TB) infection evaluation – OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with moderately to severely active rheumatoid arthritis or severe alopecia areata, consider treatment for TB prior to OLUMIANT use .
Viral hepatitis screening in accordance with clinical guidelines .
Complete blood count – Assess baseline values and verify whether treatment can be initiated:
In patients with moderately to severely active rheumatoid arthritis or severe alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/μl, absolute neutrophil count (ANC) <1000 cells/μl, or hemoglobin level <8 g/dL.
In patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/μl or if the ANC is <500 cells/μl.
Monitor complete blood counts during treatment and modify dosage as recommended .
Baseline hepatic and renal function – Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities .
In patients with moderately to severely active rheumatoid arthritis or severe alopecia areata, update immunizations in agreement with current immunization guidelines .
The recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food . An alternative administration for patients unable to swallow tablets may be used . OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
The recommended dosage of OLUMIANT for adults is 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first. An alternative administration for patients unable to swallow tablets may be used .
The recommended dosage of OLUMIANT for adults and pediatric patients 12 years of age and older is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate.
For adults and pediatric patients 12 years of age and older with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily, with or without food.
Once patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg once daily.
Moderately to Severely Active Rheumatoid Arthritis and Severe Alopecia Areata
Avoid use of OLUMIANT in patients with active, serious or opportunistic infection, including localized infections. If a patient develops a serious infection hold treatment with OLUMIANT until the infection is controlled . …
How to take Baricitinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Infections
Inform patients that they may be more likely to develop infections when taking OLUMIANT. Instruct patients to tell their healthcare provider if they develop any signs or symptoms of an infection .
Advise patients that the risk of herpes zoster is increased in patients treated with OLUMIANT and some cases can be serious .
Malignancy and Lymphoproliferative Disorders
Inform patients that OLUMIANT may increase their risk of developing lymphomas and other malignancies, including of the skin and that periodic skin examinations should be performed while using OLUMIANT. Instruct patients to inform their healthcare provider if they have ever had any type of cancer .
Major Adverse Cardiovascular Events
Inform patients that OLUMIANT may increase their risk of major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular death. Instruct all patients, especially current or past smokers or patients with other cardiovascular risk factors, to be alert for the development of signs and symptoms of cardiovascular events . …
Warnings & precautions
Do not take this medicine if: None.
Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection . Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Avoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients:
with chronic or recurrent infection
who have been exposed to tuberculosis
with a history of a serious or an opportunistic infection
who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or
with underlying conditions that may predispose them to infection.
In patients with rheumatoid arthritis or alopecia areata, closely monitor for the development of signs and symptoms of infection during and after treatment with OLUMIANT. Interrupt OLUMIANT in patients with rheumatoid arthritis or alopecia areata, if the patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and OLUMIANT should be interrupted if the patient is not responding to therapy. …
Baricitinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Serious Infections
Mortality
Malignancy and Lymphoproliferative Disorders
Major Adverse Cardiovascular Events
Thrombosis
Hypersensitivity
Gastrointestinal Perforations
Hypoglycemia in Patients with Diabetes
Laboratory Abnormalities
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.
Moderately to Severely Active Rheumatoid Arthritis
The safety of OLUMIANT was evaluated in six randomized double-blind placebo-controlled studies (three Phase 2, three Phase 3) and a long-term extension study in subjects with moderately to severely active RA. Subjects were randomized to placebo (1070 subjects), OLUMIANT 2 mg (479 subjects), or baricitinib 4 mg (997 subjects).
Subjects could be switched to baricitinib 4 mg from placebo or OLUMIANT 2 mg from as early as Week 12 depending on the study design. All subjects initially randomized to placebo were switched to baricitinib 4 mg by Week 24. …
Drug interactions
Baricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid), hence the dosage of baricitinib should be reduced by half the recommended dose .
OLUMIANT has not been studied in combination with other JAK inhibitors or with biologic DMARDs .
About this medicine
OLUMIANT (baricitinib) is a Janus kinase (JAK) inhibitor with the chemical name {1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile. Baricitinib has an empirical formula of C16H17N7O2S and a molecular weight of 371.42. Baricitinib has the following structural formula:
OLUMIANT tablets contain a recessed area on each face of the tablet surface and are available for oral administration as debossed, film-coated tablets. The 1 mg tablet is very light pink, round, debossed with “Lilly” on one side and “1” on the other. The 2 mg tablet is light pink, oblong, debossed with “Lilly” on one side and “2” on the other. The 4 mg tablet is medium pink, round, debossed with “Lilly” on one side and “4” on the other.
Each tablet contains 1, 2, or 4 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, ferric oxide, lecithin (soya), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
How it works: Baricitinib is a Janus kinase (JAK) inhibitor. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 866e9f35-9035-4581-a4b1-75a621ab55cf. Read the full official label on DailyMed.
Related medicines
Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine